“Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b 4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s420, https://doi.org/10.25251/skin.8.supp.420.